Naseem Zojwalla
Chief Tech/Sci/R&D Officer bij OLEMA PHARMACEUTICALS, INC.
Vermogen: 909 720 $ op 31-03-2024
Actieve functies van Naseem Zojwalla
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
OLEMA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31-01-2022 | - |
TURG POIN | Chief Tech/Sci/R&D Officer | - | - |
PELOTON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - | - |
Columbia University Medical Center | Corporate Officer/Principal | - | - |
Loopbaan van Naseem Zojwalla
Opleiding van Naseem Zojwalla
Stanford University | Undergraduate Degree |
Temple University School of Medicine | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 7 |
Operationeel
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
OLEMA PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Peloton Therapeutics, Inc.
Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Beurs
- Insiders
- Naseem Zojwalla
- Ervaring